Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on Awareness
June 9, 2015 12:04 PM EDTRBC Capital analyst Adnan Butt weighed in on MannKind (NASDAQ: MNKD) after partner Sanofi's (NYSE: SNY) update at ADA included Afrezza where it highlighted selling efforts will pick up in second-half. While discussion was modest, SNY plans a more direct patient focus in second half, the analyst comments.
Butt said while while they would have appreciated greater focus, given investments and plans for second half, SNY appears committed to Afrezza for now. He said what matters still is: 1) the growth trajectory in prescriptions 2) hurdles getting worked out, 3) whether... More
